Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
ATOS 10.14.2024
Date of Upcoming Event:2024-10-16
Name of Upcoming Event:2024 Maxim Healthcare Virtual Summit

About Gravity Analytica
Recent News
- 01.06.2025 - Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer
- 12.12.2024 - Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
- 12.11.2024 - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Recent Filings
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) --Atossa Therapeutics, Inc.(Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Interested parties can register and access the live webcast for the conferencehere.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visitwww.atossatherapeutics.com.
Contact:Michael ParksVice President, Investor and Public Relations484-356-7105michael.parks@atossainc.com
